All 50 states sign up for Trump's Medicaid most-favored-nation plan

Medicaid, funded jointly by state and federal governments, already draws steep discounts from drugmakers, mandated by existing law. Most people covered by the health program for low-income Americans pay little out of pocket for prescriptions.

Last month, the administration announced a new round of drug-pricing agreements with international pharmaceutical companies and some smaller biotech firms.

The biggest savings so far from the MFN deals have come from weight-loss drugs. Novo and Lilly agreed to price cuts in return for their medicines being made more available through the Medicare program.

But beyond weight-loss drugs, critics have been skeptical about how much price relief Americans are really receiving from the White House agreements.

Steve Ubl, chief executive of industry lobby group PhRMA, criticized the new policies as "importing foreign prices from socialist countries."